scholarly journals Personalizing Heart Failure Care to the Patient With Cancer

Author(s):  
Ekaterini Lambrinou ◽  
Julia Decourcey ◽  
Loreena Hill
2016 ◽  
Vol 23 (4) ◽  
pp. 24-29 ◽  
Author(s):  
Hiba Deek ◽  
Phillip J Newton ◽  
Samar Noureddine ◽  
Sally C Inglis ◽  
Ghina Al Arab ◽  
...  

2015 ◽  
Vol 21 (8) ◽  
pp. S61
Author(s):  
Harleen Singh ◽  
Jessina C. McGregor ◽  
Cindy L. Quale ◽  
Kelsie W. Flynn ◽  
Samaneh Zhian ◽  
...  

2015 ◽  
Vol 12 (2) ◽  
pp. 173-186 ◽  
Author(s):  
P. Iyngkaran ◽  
S. R. Toukhsati ◽  
N. Biddagardi ◽  
H. Zimmet ◽  
J. J.Atherton ◽  
...  

Heart & Lung ◽  
2021 ◽  
Vol 50 (5) ◽  
pp. 622-626
Author(s):  
Sijia Wei ◽  
Eleanor S. McConnell ◽  
Kirsten N. Corazzini ◽  
James Moody ◽  
Wei Pan ◽  
...  

2017 ◽  
Vol 33 (11) ◽  
pp. 1434-1449 ◽  
Author(s):  
Michael A. McDonald ◽  
Euan A. Ashley ◽  
Paul W.M. Fedak ◽  
Nathaniel Hawkins ◽  
James L. Januzzi ◽  
...  

2020 ◽  
Vol 15 (9) ◽  
pp. 1-9
Author(s):  
Marianne O'Hara ◽  
Amanda Smith ◽  
Emma Foster ◽  
Stephen J Leslie

Introduction: This project aimed to assess and optimise the treatment of all patients with heart failure with reduced ejection fraction (HFrEF). Methods: Consecutive patients discharged with a heart failure code (ICD-10) between April 2014 and July 2017 were included. The medical records were reviewed to ensure optimal medical therapy and in cases where this was not being received, a process of ‘active optimisation’ was initiated. Results: Out of 656 patients, 139 were identified as eligible for guideline-directed treatment, 129 (93%) of which were receiving optimal medical therapy. Of these, 47 (36%) were deemed to be optimised but were not on full guideline-directed therapy owing to contraindication, intolerance, comorbidities or non-compliance. Conclusion: The project data reflect real-world patients and practice and highlight a tension between guideline-based care and real-life (realistic) medicine.


Sign in / Sign up

Export Citation Format

Share Document